Alexandre V. Hirayama, MD

About Dr. Hirayama

Dr. Hirayama is a hematologist-oncologist specializing in the treatment of blood cancers with a focus on blood and marrow transplantation and advanced cellular immunotherapies. As a faculty member at Fred Hutchinson Cancer Center and the University of Washington School of Medicine, Dr. Hirayama is deeply engaged in the clinical care of patients undergoing chimeric antigen receptor (CAR) T-cell therapy—an innovative approach that uses genetically engineered immune cells to fight cancer.

His research leverages cutting-edge technologies to explore the biological and clinical factors that influence outcomes following immunotherapy, particularly CD19-directed CAR T-cell treatments. By combining translational science with clinical expertise, Dr. Hirayama aims to design and lead clinical trials that optimize the effectiveness of immunotherapies and improve long-term outcomes for patients.

Dr. Hirayama holds appointments as a member of the Immunotherapy Integrated Research Center and as an affiliate investigator in the Translational Science and Therapeutics Division at Fred Hutch. He earned his medical degree from the University of Brasília and completed advanced training in internal medicine, hematology, and hematopoietic cell transplantation at the University of São Paulo School of Medicine. He continued his research training with post-doctoral fellowships and a physician scholar program at Fred Hutch.

His clinical and research interests align closely around improving immune-based treatments through a better understanding of T-cell biology and treatment kinetics. Dr. Hirayama’s work supports the development of more precise and effective therapeutic approaches in the rapidly evolving field of cellular immunotherapy.